Vaccine Damage Payment Scheme: Coronavirus
The question
To ask the Secretary of State for Health and Social Care, how many and what proportion of applications to the Vaccine Damage Payment Scheme relating to Covid-19 vaccinations have been (a) made and (b) successful for (i) Vaccine-induced thrombocytopenia and thrombosis, (ii) Guillain-Barré syndrome and (iii) other conditions.
Answered by Andrew Gwynne
As of 3 January 2025, the NHS Business Services Authority (NHS BSA) had received 183 assessed claims to the Vaccine Damage Payment Scheme (VDPS) relating to COVID-19 for vaccine-induced thrombocytopenia and thrombosis. These 183 claims reflect 1.9% of the total number of claims which have undergone a completed medical assessment. Of these 183 claims, 92, or 50.3%, have been successful. The NHS BSA also received 224 assessed claims to the VDPS relating to COVID-19 for Guillain-Barré syndrome. These 224 claims reflect 2.3% of the total number of claims which have undergone a completed medical assessment. Of these 224 claims, 63, or 28.1%, have been successful. Finally, the NHS BSA also received 9,480 assessed claims to the VDPS relating to COVID-19 for other conditions. These 9,480 claims reflect 95.9% of the total number of claims which have undergone a completed medical assessment. Of these 9,480 claims, 199, or 2.1%, have been successful.
These figures reflect conditions which have been identified from the medical records of claimants. Claims may relate to a combination of these conditions and other conditions from the medical records of claimants.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →